Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Christian Rolfo

Dr. Christian Rolfo

Director, Thoracic Medical Oncology and Early Clinical Trials

Dr. Christian Rolfo is the director of Thoracic Medical Oncology and Early Clinical Trials at the University of Maryland Greenebaum Comprehensive Cancer Center in Baltimore.

Get in touch
Jump to a Topic:

About Christian Rolfo

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • Team Leader icon

    Team Leader

  • Board Certified icon

    Board Certified in Medical Oncology

Rolfo specializes in treatment for thoracic malignancies such as lung cancer and pleural mesothelioma, translational oncology and new drug development.

He joined the Greenebaum Cancer Center in 2018 after six years at the Antwerp University Hospital in Belgium, where he served as director of the Clinical Trials Management Program.

His research focus has been the personalization of treatment through biomarkers and immunotherapy for thoracic cancers.

“We have immunotherapy treatment today that can be specific to tumors and attack cancer cells,” Rolfo said. “We are diagnosing genetic alterations for more targeted therapy today. The results have been encouraging.”

He also serves as a professor in the Division of Hematology-Oncology at the Maryland School of Medicine.

His work has been published in the New England Journal of Medicine, Lung Cancer, Lancet Oncology and Nature Nanotechnology.

Rolfo received his medical degree from the National University of Cordoba, Argentina, in 1996. He completed a residency at the University of Milan, Italy, and did an internship at the MD Anderson Cancer Center in Houston.

He is part of the Educational Committee of the International Association for the Study of Lung Cancer and on the Membership Committee of the European Society of Medical Oncology.

Immunotherapy Advancements from Dr. Christian Rolfo

In 2019, Rolfo co-authored a study with Dr. Charles Simone that detailed the effectiveness of combining immune checkpoint inhibitor drugs, such as Opdivo and Keytruda, with proton beam therapy for mesothelioma.

The International Association for the Study of Lung Cancer published another of Rolfo’s studies in 2019 on the advantages of liquid biopsies as an alternative to traditional tissue biopsies for non-small cell lung cancer.

He detailed multiple clinical uses, including biomarker identification, improved patient selection for treatment and drug resistance monitoring.

Rolfo was appointed vice-president of the International Society of Liquid Biopsy, a nonprofit organization that works toward erasing restrictions on liquid biopsy implementation in routine clinical practice.

He also has written on patient selection for immunotherapy treatment with solid tumors, the use of ipilimumab for treating non-small cell lung cancer, and the role of circulating tumor DNA in lung cancer.

Disclaimer: Dr. Christian Rolfo has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Daniel King, Content Writer for
Edited by

3 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Journal of Thoracic Oncology. (2019, September). Proton Beam Therapy and Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma.
    Retrieved from:
  2. IASLC Lung Cancer News. (2019, August 14). Christian Rolfo.
    Retrieved from:
  3. University of Maryland Medical System. (n.d.). Christian Rolfo, MD. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified August 19, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now